Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis

BACKGROUND: Rifapentine-based regimens have potent antimycobacterial activity that may allow for a shorter course in patients with drug-susceptible pulmonary tuberculosis. METHODS: In an open-label, phase 3, randomized, controlled trial involving persons with newly diagnosed pulmonary tuberculosis f...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:N Engl J Med
Autori principali: Dorman, Susan E., Nahid, Payam, Kurbatova, Ekaterina V., Phillips, Patrick P.J., Bryant, Kia, Dooley, Kelly E., Engle, Melissa, Goldberg, Stefan V., Phan, Ha T.T., Hakim, James, Johnson, John L., Lourens, Madeleine, Martinson, Neil A., Muzanyi, Grace, Narunsky, Kim, Nerette, Sandy, Nguyen, Nhung V., Pham, Thuong H., Pierre, Samuel, Purfield, Anne E., Samaneka, Wadzanai, Savic, Radojka M., Sanne, Ian, Scott, Nigel A., Shenje, Justin, Sizemore, Erin, Vernon, Andrew, Waja, Ziyaad, Weiner, Marc, Swindells, Susan, Chaisson, Richard E.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2021
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8282329/
https://ncbi.nlm.nih.gov/pubmed/33951360
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa2033400
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi